Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 ...Middle East

Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 Study of Subcutaneous...

Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024 )

Also on site :

• BetMGM Bonus Code NW150: Get Latest $150 Bonus for NBA, NHL, UFC 315
• LSU sees 4-star 2026 WR flip commitment to SMU
• 43 Mother's Day Dessert Recipes to Satisfy Every Type of Sweet Tooth